These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27324802)

  • 1. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.
    Heinz WJ; Buchheidt D; Ullmann AJ
    Mycoses; 2016 Aug; 59(8):480-93. PubMed ID: 27324802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.
    Groetzner J; Kaczmarek I; Wittwer T; Strauch J; Meiser B; Wahlers T; Daebritz S; Reichart B
    J Heart Lung Transplant; 2008 Jan; 27(1):1-6. PubMed ID: 18187079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspofungin: a review of its use in the treatment of fungal infections.
    McCormack PL; Perry CM
    Drugs; 2005; 65(14):2049-68. PubMed ID: 16162025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
    Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA
    J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study.
    León-Gil C; Ubeda-Iglesias A; Loza-Vázquez A; de la Torre MV; Raurich-Puigdevall JM; Alvarez-Sánchez B; Ortiz-Leyva C; Domínguez-Roldán JM; Socías-Crespi L; Garnacho-Montero J;
    Rev Esp Quimioter; 2012 Dec; 25(4):274-82. PubMed ID: 23303260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspofungin for treatment of invasive aspergillus infections.
    Heinz WJ; Einsele H
    Mycoses; 2008; 51 Suppl 1():47-57. PubMed ID: 18471161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caspofungin acetate for treatment of invasive fungal infections.
    Pacetti SA; Gelone SP
    Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspofungin: first approved agent in a new class of antifungals.
    Johnson MD; Perfect JR
    Expert Opin Pharmacother; 2003 May; 4(5):807-23. PubMed ID: 12740003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspofungin therapy in immunocompromised children and neonates.
    Somer A; Törün SH; Salman N
    Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis.
    Cornely OA; Meems L; Herbrecht R; Viscoli C; van Amsterdam RG; Ruhnke M
    Mycoses; 2015 Jan; 58(1):58-64. PubMed ID: 25530265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
    Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
    Maertens J; Egerer G; Shin WS; Reichert D; Stek M; Chandwani S; Shivaprakash M; Viscoli C;
    BMC Infect Dis; 2010 Jun; 10():182. PubMed ID: 20569436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
    Groll AH; Walsh TJ
    Expert Opin Investig Drugs; 2001 Aug; 10(8):1545-58. PubMed ID: 11772269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
    Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
    Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.